Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Johnson & Johnson

NEW BRUNSWICK, N.J., Aug. 19, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc.

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases

Here's Why Momenta Pharmaceuticals Dropped 13.5% Today

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q2 2020 Results - Earnings Call Transcript

Momenta (MNTA) delivered earnings and revenue surprises of -14.29% and 13.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Tops Revenue Estimates

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) rose 1% after the company reported Q2 results.

Recap: Momenta Pharmaceuticals Q2 Earnings

-- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p

Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results

CAMBRIDGE, Mass., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020.

Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

CAMBRIDGE, Mass., July  28, 2020  (GLOBE NEWSWIRE) --  Momenta Pharmaceuticals, Inc.  (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic disease of the fetus and newborn (HDFN). Additionally, FDA granted nipocalimab orphan drug designation in HDFN. HDFN is a serious blood disorder in a fetus or newborn that occurs when red blood cell incompatibility exists between the blood types of a mother and fetus in utero.

Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN

Momenta (MNTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Momenta (MNTA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Clearwater Paper

Commercial Metals

Domo

ViewRay

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

5 Top Momentum Stocks of June Amid Resurgence of Coronavirus

As of late, it has definitely been a great time to be an investor in Momenta Pharmaceuticals, Inc. (MNTA).

Momenta Pharmaceuticals, Inc. (MNTA) Shares March Higher, Can It Continue?

Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.

Momenta (MNTA) Up on Positive Data From Generalized MG Drug

Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.

Here's Why Momenta Jumped Higher Today

- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p

Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock?

Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?

Here’s why this drugmaker targeting autoimmune conditions and rare diseases is a solid buy.

Is Momenta Pharmaceuticals' Stock a Buy?

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2020 Results - Earnings Call Transcript

Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass., April  02, 2020  (GLOBE NEWSWIRE) --  Momenta Pharmaceuticals, Inc.  (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today provided an update on the Company’s clinical trial activities and business operations in light of  the COVID-19 pandemic.

Momenta Provides Corporate Update Amid COVID-19 Pandemic

Momenta (MNTA) Down 0.3% Since Last Earnings Report: Can It Rebound?

Biogen

BioMarin Pharmaceutical

Emergent BioSolutions

Mylan

Novavax

An overall market rebound and a presidential press conference carried several biotech and pharmaceutical stocks markedly higher.

Why These Drug Stocks Soared Today

Investors ran back into the stock after one of the worst weeks in market history. Will it prove sustainable?

Here's Why Momenta Pharmaceuticals Stock Rose 10.8% on Monday

Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat

Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q4 2019 Results - Earnings Call Transcript

News for Momenta Pharmaceuticals Stock (MNTA)